Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arm 3 Clear all
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

NCT04047849
View directory record Official record
Conditions
Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture), Rupture of Membranes; Premature, Rupture of Membranes; Premature, Affecting Fetus, Preterm Birth, Preterm PROM (Pregnancy), Preterm Labor
Interventions
Antibiotics, oral Azithromycin and oral Amoxicillin
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing a Life Skills Application to Address Interpersonal Relationships in College (MKit)

NCT03715426
View directory record Official record
Conditions
Sexual Violence, Primary Prevention
Interventions
MKit
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 4, 2026, 5:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

NCT04161885
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Cancer
Interventions
Venetoclax, Azacitidine, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 4, 2026, 5:51 AM EDT
Recruiting Not applicable Interventional

Empowered Relief® for Cancer Survivors With Chronic Pain

NCT07578376
View directory record Official record
Conditions
Chronic Pain Due to Cancer, Pain Catastrophizing
Interventions
Empowered Relief Course (Zoom)
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 120 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Encouraging Judicious Prescribing of Opioids in Los Angeles County

NCT03856593
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Standard letter, Comparator letter
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

NCT01090921
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

NCT02004106
View directory record Official record
Conditions
Neoplasms
Interventions
RO6895882
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 4, 2026, 5:51 AM EDT
Active, not recruiting No phase listed Observational

Pharmacist-led Continuous Glucose Monitoring

NCT06572306
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
FreeStyle Libre 2/Libre 3+ Continuous Glucose Monitor
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

NCT01909752
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cyclophosphamide, DRibble vaccine, Imiquimod, GM-CSF, HPV vaccine
Drug · Biological
Lead sponsor
UbiVac
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

FITBIT Study on Mobility and Readmissions After Radical Cystectomy

NCT04314778
View directory record Official record
Conditions
Bladder Cancer
Interventions
social incentive-based gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 4, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01192815
View directory record Official record
Conditions
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
Drug · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

NCT00563576
View directory record Official record
Conditions
Metrorrhagia
Interventions
Femring®, DepoProvera ®
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

RegoNivo vs Standard of Care Chemotherapy in AGOC

NCT04879368
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Drug · Biological
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
86
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

NCT01754389
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Tacrolimus, Methotrexate, Bortezomib, Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 4, 2026, 5:51 AM EDT
Recruiting Phase 1 Interventional

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04837547
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 1 Interventional

Bright Light on Fatigue in Women Being Treated for Breast Cancer

NCT02658708
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions
Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Digital foot candle datalogging light meter (Extech Instrument, Model SDL400), Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA), Horne-Ostberg Morningness-Eveningness Questionnaire, Daily Fatigue and Sleep Log
Other · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Not applicable Interventional Results available

Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI

NCT02314221
View directory record Official record
Conditions
Spinal Cord Injury, Paraplegia, Tetraplegia
Interventions
Exoskeletal-assisted walking (ReWalk, Ekso)
Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Management of Postoperative Pain After Total Knee Replacement.

NCT01163214
View directory record Official record
Conditions
Postoperative Pain, Knee Replacement Arthroplasty
Interventions
Nerve Block, Periarticular Injection
Drug
Lead sponsor
Mark J. Spangehl, M.D.
Other
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 4, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533
View directory record Official record
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
36
States / cities
Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 4, 2026, 5:51 AM EDT